"Pharma Giants Face Revenue Loss as Blockbuster Drugs Near Patent Expiry"
Originally Published 1 year ago — by CNBC
Big pharmaceutical companies like J&J, Merck, and Bristol Myers Squibb are facing a significant revenue threat as patents for their blockbuster drugs expire, allowing competitors to sell cheaper copycats. This could result in tens of billions of dollars in lost sales by 2030. Companies are preparing to offset these losses by building drug pipelines, making acquisitions, and entering partnerships. The looming patent cliffs and potential Medicare drug price negotiations pose challenges, but companies are exploring strategies such as developing new drug formulations and settling lawsuits to delay competition and extend patent protections.